ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity

ZyVersa Therapeutics, a clinical stage specialty biopharmaceutical company, has announced the publication of an article in Clinical Immunology that demonstrates the association between renal NLRP3 inflammasome activation and lupus nephritis disease activity. Lupus nephritis is characterized by inflammation in the kidney, protein leakage into the urine, and progressive kidney damage. The study fo..